{"id":548729,"date":"2026-09-07T15:15:40","date_gmt":"2026-09-07T15:15:40","guid":{"rendered":"https:\/\/www.newjerseyheadlines.com\/news\/story\/548729\/metastatic-her2positive-breast-cancer-market-to-grow-at-83-cagr-through-2036-driven-by-rising-adoption-of-her2targeted-therapies-and-nextgeneration-adcs-delveinsight.html"},"modified":"2026-09-07T15:15:40","modified_gmt":"2026-09-07T15:15:40","slug":"metastatic-her2positive-breast-cancer-market-to-grow-at-83-cagr-through-2036-driven-by-rising-adoption-of-her2targeted-therapies-and-nextgeneration-adcs-delveinsight","status":"publish","type":"post","link":"http:\/\/www.northcarolinaheadlines.com\/news\/story\/548729\/metastatic-her2positive-breast-cancer-market-to-grow-at-83-cagr-through-2036-driven-by-rising-adoption-of-her2targeted-therapies-and-nextgeneration-adcs-delveinsight.html","title":{"rendered":"Metastatic HER2-positive Breast Cancer Market to Grow at 8.3% CAGR Through 2036, Driven by Rising Adoption of HER2-targeted Therapies and Next-generation ADCs | DelveInsight"},"content":{"rendered":"<div style=\"float:right;width:250px;padding:8px 10px 10px 10px\"><a rel=\"nofollow noopener\" href=\"https:\/\/www.abnewswire.com\/upload\/2026\/09\/1788761356.jpg\" style=\"border:none !important\" target=\"_blank\"><img decoding=\"async\" loading=\"lazy\" class=\"alignnone size-medium wp-image-29\" title=\"Metastatic HER2-positive Breast Cancer Market to Grow at 8.3% CAGR Through 2036, Driven by Rising Adoption of HER2-targeted Therapies and Next-generation ADCs | DelveInsight\" src=\"https:\/\/www.abnewswire.com\/upload\/2026\/09\/1788761356.jpg\" alt=\"Metastatic HER2-positive Breast Cancer Market to Grow at 8.3% CAGR Through 2036, Driven by Rising Adoption of HER2-targeted Therapies and Next-generation ADCs | DelveInsight\" width=\"225\" height=\"118\" \/><\/a><\/div>\n<div style=\"font-style:italic;padding:8px 0px\">DelveInsight\u2019s latest report, \u201cMetastatic HER2-positive Breast Cancer Market Insights, Epidemiology and Market Forecast \u2013 2036,\u201d provides a comprehensive analysis of the metastatic HER2-positive breast cancer market across the United States, EU4, the United Kingdom, and Japan. According to DelveInsight\u2019s estimates, the metastatic HER2-positive breast cancer market size was approximately USD 2.9 billion in 2025 and is projected to grow at a CAGR of approximately 8.3% during 2026\u20132036.<\/div>\n<p style=\"text-align: justify\">(Albany, New York)- 7th Sep 2026 &#8211; DelveInsight&rsquo;s latest report, &ldquo;Metastatic HER2-positive Breast Cancer Market Insights, Epidemiology and Market Forecast &ndash; 2036,&rdquo; provides a comprehensive analysis of the metastatic HER2-positive breast cancer market across the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan. According to DelveInsight&rsquo;s estimates, the metastatic HER2-positive breast cancer market size was approximately USD 2.9 billion in 2025 and is projected to grow at a CAGR of approximately 8.3% during 2026&ndash;2036.<\/p>\n<p style=\"text-align: justify\">The metastatic HER2-positive breast cancer treatment landscape has evolved significantly with the development of HER2-directed monoclonal antibodies, antibody-drug conjugates (ADCs), tyrosine kinase inhibitors (TKIs), and fixed-dose subcutaneous combinations. Despite substantial therapeutic advances, relapse, treatment resistance, toxicity, and treatment sequencing remain important challenges, creating continued demand for novel therapies.<\/p>\n<p style=\"text-align: justify\">Key Takeaways from the Metastatic HER2-positive Breast Cancer Market<\/p>\n<ul style=\"text-align: justify\">\n<li>\n<p class=\"caps\">The metastatic HER2-positive breast cancer market size was approximately USD 2.9 billion in 2025 and is expected to grow at approximately 8.3% CAGR during 2026&ndash;2036.<\/p>\n<\/li>\n<li>\n<p>The total incident population of HER2-positive breast cancer in the 7MM was nearly 104,000 cases in 2025.<\/p>\n<\/li>\n<li>\n<p>The United States accounted for approximately 60% of the total HER2-positive breast cancer market in the 7MM in 2025.<\/p>\n<\/li>\n<li>\n<p>The United States had approximately 14,500 metastatic HER2-positive breast cancer cases in the treatment-eligible pool in 2025.<\/p>\n<\/li>\n<li>\n<p>In the United States, approximately 52% of HER2-positive breast cancer cases occurred among individuals aged 40&ndash;60 years in 2025.<\/p>\n<\/li>\n<li>\n<p>Among EU4 and the UK, Germany recorded the highest number of HER2-positive breast cancer incident cases, with approximately 10,800 cases in 2025.<\/p>\n<\/li>\n<li>\n<p>HER2-targeted therapies, including HERCEPTIN, PERJETA, KADCYLA, ENHERTU, TUKYSA, and PHESGO, continue to shape the treatment landscape.<\/p>\n<\/li>\n<li>\n<p>ADCs are emerging as a major therapeutic class, with next-generation agents being developed to address resistance and improve outcomes following treatment with established HER2-directed therapies.<\/p>\n<\/li>\n<li>\n<p>Key companies involved in the market include Byondis, Roche, Pfizer, Ambrx, Bolt Biotherapeutics, BioInvent International AB, Klus Pharma, DualityBio, Artiva Biotherapeutics, Vaccinex, Suzhou Zanrong Pharma, Dizal Pharmaceuticals, and others.<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify\">Keen to know more about the Metastatic HER2-positive Breast Cancer Market Report?<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/metastatic-her2-positive-breast-cancer-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=kspr\">https:\/\/www.delveinsight.com\/sample-request\/metastatic-her2-positive-breast-cancer-market<\/a><\/p>\n<p style=\"text-align: justify\">Key Factors Driving the Metastatic HER2-positive Breast Cancer MarketRising Disease Burden and Patient Pool<\/p>\n<p style=\"text-align: justify\">HER2-positive breast cancer represents approximately 15&ndash;20% of breast cancer cases, and a meaningful proportion of these patients eventually develop metastatic disease. The growing patient pool requiring long-term systemic treatment is expected to sustain demand for effective HER2-directed therapies throughout the forecast period.<\/p>\n<p style=\"text-align: justify\">Strong Uptake of HER2-targeted Therapies<\/p>\n<p style=\"text-align: justify\">The continued use of established HER2-directed therapies and adoption of newer targeted agents are important contributors to market growth. HERCEPTIN and PERJETA remain central to treatment strategies, while ENHERTU, KADCYLA, TUKYSA, PHESGO, and other agents have expanded treatment options across different lines of therapy.<\/p>\n<p style=\"text-align: justify\">Increasing Adoption of Antibody-drug Conjugates<\/p>\n<p style=\"text-align: justify\">The development of ADCs has significantly transformed the treatment of metastatic HER2-positive breast cancer. ENHERTU and KADCYLA have demonstrated the potential of targeted delivery of cytotoxic payloads, while emerging ADCs such as SYD985 and ARX788 are being investigated to address treatment resistance and provide additional options for patients who have progressed following previous HER2-directed therapies.<\/p>\n<p style=\"text-align: justify\">Growing Focus on Novel Treatment Approaches<\/p>\n<p style=\"text-align: justify\">The market is witnessing continued development of novel HER2-directed approaches, including next-generation ADCs, TKIs, combination therapies, and therapies designed to overcome resistance mechanisms. These developments are expected to broaden the treatment landscape and create additional market opportunities.<\/p>\n<p style=\"text-align: justify\">Competitive Landscape<\/p>\n<p style=\"text-align: justify\">The metastatic HER2-positive breast cancer market includes a combination of established marketed therapies and a growing pipeline of emerging treatments.<\/p>\n<p style=\"text-align: justify\">Marketed therapies include HERCEPTIN, HERCEPTIN HYLECTA, PHESGO, KADCYLA, MARGENZA, TUKYSA, NERLYNX, PERJETA, TYKERB\/TYVERB, and ENHERTU. These therapies include HER2-targeted monoclonal antibodies, ADCs, and TKIs used across different lines of treatment.<\/p>\n<p style=\"text-align: justify\">Among emerging therapies, SYD985 (trastuzumab duocarmazine) from Byondis, ARX788 from Ambrx, BDC-1001 &plusmn; pertuzumab from Bolt Biotherapeutics, BI-1607 + trastuzumab from BioInvent International AB, and other pipeline candidates are being evaluated across different stages of clinical development.<\/p>\n<p style=\"text-align: justify\">Recent Developments in the Metastatic HER2-positive Breast Cancer Market<\/p>\n<ul style=\"text-align: justify\">\n<li>\n<p>December 2025: The US FDA approved ENHERTU (fam-trastuzumab deruxtecan-nxki) in combination with pertuzumab for the first-line treatment of adults with unresectable or metastatic HER2-positive breast cancer.<\/p>\n<\/li>\n<li>\n<p>October 2025: Pfizer announced positive topline results from the Phase III HER2CLIMB-05 trial evaluating TUKYSA in a first-line combination setting for patients with HER2-positive metastatic breast cancer.<\/p>\n<\/li>\n<li>\n<p>December 2025: Pfizer announced detailed results from HER2CLIMB-05 evaluating TUKYSA as part of an investigational first-line maintenance treatment combination following chemotherapy-based induction.<\/p>\n<\/li>\n<li>\n<p>May 2023: The US FDA issued a Complete Response Letter concerning the biologics license application for SYD985 (trastuzumab duocarmazine) for HER2-positive unresectable, locally advanced, or metastatic breast cancer.<\/p>\n<\/li>\n<li>\n<p>March 2024: Johnson &amp; Johnson announced the successful acquisition of Ambrx Biopharma, providing an opportunity to develop and commercialize targeted oncology therapeutics, including ARX788.<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify\">What is Metastatic HER2-positive Breast Cancer?<\/p>\n<p style=\"text-align: justify\">HER2-positive breast cancer is a subtype of breast cancer characterized by overexpression or amplification of the human epidermal growth factor receptor 2 (HER2) gene or protein. HER2-positive disease tends to grow more rapidly and has a greater likelihood of spreading or recurring than HER2-negative disease.<\/p>\n<p style=\"text-align: justify\">HER2 status is generally determined through biomarker testing, including immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH). Tumors classified as IHC 3+ or FISH-positive are generally considered HER2-positive and are candidates for HER2-targeted therapies.<\/p>\n<p style=\"text-align: justify\">Metastatic HER2-positive breast cancer refers to HER2-positive breast cancer that has spread beyond the breast and regional lymph nodes to distant organs. Treatment primarily involves systemic therapies, including HER2-targeted monoclonal antibodies, ADCs, TKIs, chemotherapy, and hormonal therapy in patients with hormone receptor-positive disease.<\/p>\n<p style=\"text-align: justify\">Current Treatment Landscape<\/p>\n<p style=\"text-align: justify\">The treatment landscape for metastatic HER2-positive breast cancer has transitioned from conventional chemotherapy toward highly targeted, biomarker-driven treatment strategies.<\/p>\n<p style=\"text-align: justify\">HERCEPTIN (trastuzumab) and PERJETA (pertuzumab) form the backbone of HER2-targeted therapy, particularly in first-line treatment. ADCs such as ENHERTU and KADCYLA deliver cytotoxic payloads directly to HER2-expressing cancer cells, while TKIs such as TUKYSA, NERLYNX, and TYKERB\/TYVERB provide oral HER2-directed treatment options, particularly in later-line or refractory settings.<\/p>\n<p style=\"text-align: justify\">Despite substantial improvements in outcomes, resistance to HER2-directed therapies, ADC resistance, treatment-related toxicity, and poor overall survival in advanced disease continue to represent important unmet needs.<\/p>\n<p style=\"text-align: justify\">Metastatic HER2-positive Breast Cancer Epidemiology Segmentation<\/p>\n<p style=\"text-align: justify\">The epidemiology analysis covers:<\/p>\n<ul style=\"text-align: justify\">\n<li>\n<p>Total Incidence Cases of Breast Cancer<\/p>\n<\/li>\n<li>\n<p>Total Incident Cases of HER2-positive Breast Cancer<\/p>\n<\/li>\n<li>\n<p>Hormonal Status of HER2-positive Breast Cancer<\/p>\n<\/li>\n<li>\n<p>Age-specific Cases of HER2-positive Breast Cancer<\/p>\n<\/li>\n<li>\n<p>Stage-specific Cases of HER2-positive Breast Cancer<\/p>\n<\/li>\n<li>\n<p>Line-wise Metastatic Cases of HER2-positive Breast Cancer<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify\">According to DelveInsight, the total incident population of HER2-positive breast cancer in the 7MM was nearly 104,000 cases in 2025. The United States accounted for approximately 14,500 metastatic HER2-positive breast cancer cases in the treatment-eligible pool, while Germany recorded approximately 10,800 total incident HER2-positive breast cancer cases among EU4 and the UK in 2025.<\/p>\n<p style=\"text-align: justify\">Scope of the Metastatic HER2-positive Breast Cancer Market Report<\/p>\n<ul style=\"text-align: justify\">\n<li>\n<p>Study Period: 2022&ndash;2036<\/p>\n<\/li>\n<li>\n<p>Historical Year: 2022&ndash;2025<\/p>\n<\/li>\n<li>\n<p>Forecast Period: 2026&ndash;2036<\/p>\n<\/li>\n<li>\n<p>Base Year: 2026<\/p>\n<\/li>\n<li>\n<p>Geographies Covered: United States, Germany, France, Italy, Spain, United Kingdom, and Japan<\/p>\n<\/li>\n<li>\n<p>Market CAGR: Approximately 8.3% during 2026&ndash;2036<\/p>\n<\/li>\n<li>\n<p>Epidemiology Segmentation: Total incidence cases of breast cancer, total incident cases of HER2-positive breast cancer, hormonal status, age-specific cases, stage-specific cases, and line-wise metastatic cases of HER2-positive breast cancer<\/p>\n<\/li>\n<li>\n<p>Market Segmentation: Region\/Geographies, Drugs\/Therapies, and Line of Therapies<\/p>\n<\/li>\n<li>\n<p>Key Companies Covered: Byondis, Roche, Pfizer, Ambrx, Bolt Biotherapeutics, BioInvent International AB, Klus Pharma, DualityBio, Artiva Biotherapeutics, Vaccinex, Suzhou Zanrong Pharma, Dizal Pharmaceuticals, and others<\/p>\n<\/li>\n<li>\n<p>Key Therapies Covered: HERCEPTIN, PHESGO, PERJETA, KADCYLA, NERLYNX, TUKYSA, SYD985, Zanidatamab, ARX788, A166, DB-1303, and others<\/p>\n<\/li>\n<li>\n<p>Market Analysis: Addressable patient population, market drivers and barriers, cost assumptions and pricing analogues, KOL views, SWOT analysis, reimbursement, conjoint analysis, and unmet needs<\/p>\n<\/li>\n<li>\n<p>Report Coverage: The report provides an overview of key events, disease background, causes, signs and symptoms, pathogenesis, diagnosis, treatment landscape, epidemiology forecasts, current and emerging therapies, historical and forecasted market size, market share by therapies, patient journey, treatment preferences, competitive landscape, and market opportunities across the 7MM.<\/p>\n<\/li>\n<li>\n<p>Report Insights: Patient population forecast, therapeutics market size, market opportunity, pipeline analysis, and market size and trends<\/p>\n<\/li>\n<li>\n<p>Key Strengths: Epidemiology-based bottom-up forecasting, AI-enabled market research, 11-year forecast, regional market outlook, patient burden trends, treatment addressable market, competitive landscape, major company insights, pricing and analogue assessment, drug adoption and uptake, and peak patient share analysis.<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify\">To know more about the clinical trials, emerging therapies, market landscape, and therapeutic assessment of metastatic HER2-positive breast cancer:<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/metastatic-her2-positive-breast-cancer-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=kspr\">View the Metastatic HER2-positive Breast Cancer Market Report<\/a><\/p>\n<p style=\"text-align: justify\">Table of Contents<\/p>\n<ol style=\"text-align: justify\">\n<li>\n<p>Key Insights<\/p>\n<\/li>\n<li>\n<p>Report Introduction<\/p>\n<\/li>\n<li>\n<p>Executive Summary of Metastatic HER2-positive Breast Cancer<\/p>\n<\/li>\n<li>\n<p>Key Events<\/p>\n<\/li>\n<li>\n<p>Metastatic HER2-positive Breast Cancer Market Overview<\/p>\n<\/li>\n<li>\n<p>Epidemiology and Market Forecast Methodology<\/p>\n<\/li>\n<li>\n<p>Disease Background and Overview of Metastatic HER2-positive Breast Cancer<\/p>\n<\/li>\n<li>\n<p>Epidemiology and Patient Population<\/p>\n<\/li>\n<li>\n<p>Patient Journey<\/p>\n<\/li>\n<li>\n<p>Key Endpoints<\/p>\n<\/li>\n<li>\n<p>Marketed Drugs<\/p>\n<\/li>\n<li>\n<p>Emerging Drugs<\/p>\n<\/li>\n<li>\n<p>7MM Market Analysis<\/p>\n<\/li>\n<li>\n<p>KOL Views<\/p>\n<\/li>\n<li>\n<p>Unmet Needs<\/p>\n<\/li>\n<li>\n<p>SWOT Analysis<\/p>\n<\/li>\n<li>\n<p>Market Access and Reimbursement<\/p>\n<\/li>\n<li>\n<p>Appendix<\/p>\n<\/li>\n<li>\n<p>DelveInsight Capabilities<\/p>\n<\/li>\n<li>\n<p>Disclaimer<\/p>\n<\/li>\n<li>\n<p>About DelveInsight<\/p>\n<\/li>\n<\/ol>\n<p style=\"text-align: justify\">About DelveInsight<\/p>\n<p style=\"text-align: justify\">DelveInsight is a leading market research and consulting firm specializing in the life sciences and healthcare industries. Founded in 2014, the company provides comprehensive market intelligence, epidemiology, and insights across pharmaceuticals, biotechnology, medical devices, and emerging therapies. DelveInsight helps healthcare organizations make informed strategic decisions through data-driven research and industry expertise.<\/p>\n<p><span style='font-size:18px !important'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a rel=\"nofollow\" href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_56431.html\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Kirti Sharma<br \/><strong>Email:<\/strong> <a rel=\"nofollow\" href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=metastatic-her2positive-breast-cancer-market-to-grow-at-83-cagr-through-2036-driven-by-rising-adoption-of-her2targeted-therapies-and-nextgeneration-adcs-delveinsight\">Send Email<\/a><br \/><strong>Phone:<\/strong> 9193216187<br \/><strong>Address:<\/strong>304 S. Jones Blvd #2432  <br \/><strong>City:<\/strong> Las Vegas<br \/><strong>State:<\/strong> Nevada<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a rel=\"nofollow noopener\" href=\"https:\/\/www.delveinsight.com\/\" target=\"_blank\">https:\/\/www.delveinsight.com\/<\/a><\/p>\n<p><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=metastatic-her2positive-breast-cancer-market-to-grow-at-83-cagr-through-2036-driven-by-rising-adoption-of-her2targeted-therapies-and-nextgeneration-adcs-delveinsight\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>DelveInsight\u2019s latest report, \u201cMetastatic HER2-positive Breast Cancer Market Insights, Epidemiology and Market Forecast \u2013 2036,\u201d provides a comprehensive analysis of the metastatic HER2-positive breast cancer market across the United States,<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"_links":{"self":[{"href":"http:\/\/www.northcarolinaheadlines.com\/news\/wp-json\/wp\/v2\/posts\/548729"}],"collection":[{"href":"http:\/\/www.northcarolinaheadlines.com\/news\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"http:\/\/www.northcarolinaheadlines.com\/news\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"http:\/\/www.northcarolinaheadlines.com\/news\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"http:\/\/www.northcarolinaheadlines.com\/news\/wp-json\/wp\/v2\/comments?post=548729"}],"version-history":[{"count":0,"href":"http:\/\/www.northcarolinaheadlines.com\/news\/wp-json\/wp\/v2\/posts\/548729\/revisions"}],"wp:attachment":[{"href":"http:\/\/www.northcarolinaheadlines.com\/news\/wp-json\/wp\/v2\/media?parent=548729"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"http:\/\/www.northcarolinaheadlines.com\/news\/wp-json\/wp\/v2\/categories?post=548729"},{"taxonomy":"post_tag","embeddable":true,"href":"http:\/\/www.northcarolinaheadlines.com\/news\/wp-json\/wp\/v2\/tags?post=548729"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}